JP7280254B2 - Ｃｄ１１７＋細胞を減少させるための組成物及び方法 - Google Patents

Ｃｄ１１７＋細胞を減少させるための組成物及び方法 Download PDF

Info

Publication number
JP7280254B2
JP7280254B2 JP2020523244A JP2020523244A JP7280254B2 JP 7280254 B2 JP7280254 B2 JP 7280254B2 JP 2020523244 A JP2020523244 A JP 2020523244A JP 2020523244 A JP2020523244 A JP 2020523244A JP 7280254 B2 JP7280254 B2 JP 7280254B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500375A (ja
JP2021500375A5 (https=
Inventor
アール ピアース ブラッドリー
クック マイケル
ボイタノ アンソニー
パルチョウデュリー ラーフル
マクドノー ショーン
パンワール ラジブ
グランビル ジェイコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of JP2021500375A publication Critical patent/JP2021500375A/ja
Publication of JP2021500375A5 publication Critical patent/JP2021500375A5/ja
Priority to JP2023078719A priority Critical patent/JP7641452B2/ja
Application granted granted Critical
Publication of JP7280254B2 publication Critical patent/JP7280254B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020523244A 2017-10-24 2018-10-23 Ｃｄ１１７＋細胞を減少させるための組成物及び方法 Active JP7280254B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023078719A JP7641452B2 (ja) 2017-10-24 2023-05-11 Ｃｄ１１７＋細胞を減少させるための組成物及び方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762576572P 2017-10-24 2017-10-24
US62/576,572 2017-10-24
US201762596569P 2017-12-08 2017-12-08
US62/596,569 2017-12-08
US201862632967P 2018-02-20 2018-02-20
US62/632,967 2018-02-20
US201862638053P 2018-03-02 2018-03-02
US62/638,053 2018-03-02
PCT/US2018/057180 WO2019084064A2 (en) 2017-10-24 2018-10-23 COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023078719A Division JP7641452B2 (ja) 2017-10-24 2023-05-11 Ｃｄ１１７＋細胞を減少させるための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2021500375A JP2021500375A (ja) 2021-01-07
JP2021500375A5 JP2021500375A5 (https=) 2021-12-09
JP7280254B2 true JP7280254B2 (ja) 2023-05-23

Family

ID=66247007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523244A Active JP7280254B2 (ja) 2017-10-24 2018-10-23 Ｃｄ１１７＋細胞を減少させるための組成物及び方法
JP2023078719A Active JP7641452B2 (ja) 2017-10-24 2023-05-11 Ｃｄ１１７＋細胞を減少させるための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023078719A Active JP7641452B2 (ja) 2017-10-24 2023-05-11 Ｃｄ１１７＋細胞を減少させるための組成物及び方法

Country Status (13)

Country Link
US (3) US10899843B2 (https=)
EP (1) EP3700568A4 (https=)
JP (2) JP7280254B2 (https=)
KR (1) KR20200069364A (https=)
CN (1) CN111372608B (https=)
AU (1) AU2018355244B2 (https=)
BR (1) BR112020008228A2 (https=)
CA (1) CA3079897A1 (https=)
CO (1) CO2020004906A2 (https=)
IL (1) IL274154A (https=)
MX (1) MX2020004140A (https=)
SG (1) SG11202003280SA (https=)
WO (1) WO2019084064A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183613A1 (en) 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
JP2022530443A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用
NZ781538A (en) * 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
JP2022531141A (ja) * 2019-04-24 2022-07-06 マジェンタ セラピューティクス インコーポレイテッド 遺伝子治療のコンディショニング方法
EP3958902A4 (en) * 2019-04-24 2023-01-25 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND THEIR USES
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
CA3140447A1 (en) * 2019-06-05 2020-12-10 Anthony Boitano T-cell depleting therapies
AU2021239929A1 (en) * 2020-03-16 2022-10-13 Crispr Therapeutics Ag T-cell bispecific binding proteins
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4448573A1 (en) 2021-12-16 2024-10-23 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy
IL317566A (en) 2022-07-07 2025-02-01 Cimeio Therapeutics Ag Antibodies targeting CD117
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
JP2014515030A (ja) 2011-05-12 2014-06-26 イムクローン・リミテッド・ライアビリティ・カンパニー ｃ−ＫＩＴ抗体およびその使用
WO2016142049A1 (en) 2015-03-09 2016-09-15 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
JP2016536017A (ja) 2013-11-05 2016-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト中和抗ｋｉｔ抗体及びその使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600589C1 (de) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
WO1998025957A2 (en) 1996-12-13 1998-06-18 Human Genome Sciences, Inc. HUMAN Prt1-LIKE SUBUNIT PROTEIN (hPrt1) AND HUMAN eIF4G-LIKE PROTEIN (p97) GENES
US6372448B1 (en) 1998-12-30 2002-04-16 Millennium Pharmaceuticals, Inc. Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ES2371085T3 (es) 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
ES2784829T3 (es) 2009-04-08 2020-10-01 Faulstich Heinz Dr Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
KR20120128686A (ko) 2010-02-18 2012-11-27 심포젠 에이/에스 녹농균의 혈청형 ａ 지질다당류에 대한 항체
EP2603529A1 (en) 2010-08-13 2013-06-19 Roche Glycart AG Anti-tenascin-c a2 antibodies and methods of use
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
US20120189612A1 (en) * 2011-01-25 2012-07-26 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
US9540443B2 (en) * 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
WO2015006475A1 (en) 2013-07-12 2015-01-15 Biogen Idec International Neuroscience Gmbh Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
US10421802B2 (en) 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
EP3273984B1 (en) 2015-03-25 2021-05-05 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
WO2016164745A1 (en) 2015-04-10 2016-10-13 The Methodist Hospital System Cd117 ligand-drug conjugates for targeted cancer therapy
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
KR20260018979A (ko) 2016-02-05 2026-02-09 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
BR112018071465A2 (pt) 2016-04-20 2019-02-05 Hangzhou Dac Biotech Co Ltd derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular
WO2017191579A1 (en) 2016-05-05 2017-11-09 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
IL263744B2 (en) 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
WO2018183613A1 (en) 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
JP2014515030A (ja) 2011-05-12 2014-06-26 イムクローン・リミテッド・ライアビリティ・カンパニー ｃ−ＫＩＴ抗体およびその使用
JP2016536017A (ja) 2013-11-05 2016-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト中和抗ｋｉｔ抗体及びその使用
WO2016142049A1 (en) 2015-03-09 2016-09-15 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates

Also Published As

Publication number Publication date
WO2019084064A3 (en) 2019-06-20
MX2020004140A (es) 2020-08-13
AU2018355244A1 (en) 2020-04-09
CO2020004906A2 (es) 2020-05-05
BR112020008228A2 (pt) 2020-10-13
JP2021500375A (ja) 2021-01-07
JP2023113666A (ja) 2023-08-16
SG11202003280SA (en) 2020-05-28
EP3700568A4 (en) 2021-11-10
US20190153114A1 (en) 2019-05-23
US10899843B2 (en) 2021-01-26
CN111372608A (zh) 2020-07-03
WO2019084064A4 (en) 2019-08-08
CN111372608B (zh) 2024-07-02
KR20200069364A (ko) 2020-06-16
AU2018355244B2 (en) 2025-08-28
US11958908B2 (en) 2024-04-16
WO2019084064A2 (en) 2019-05-02
CA3079897A1 (en) 2019-05-02
JP7641452B2 (ja) 2025-03-07
IL274154A (en) 2020-06-30
US20210206872A1 (en) 2021-07-08
US20240360238A1 (en) 2024-10-31
EP3700568A2 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
JP7641452B2 (ja) Ｃｄ１１７＋細胞を減少させるための組成物及び方法
US11572411B2 (en) Anti-CD117 antibodies and conjugates
JP7791923B2 (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
JP7669269B2 (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
JP2021500375A5 (https=)
JP7716399B2 (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
US20220177575A1 (en) Anti-cd117 antibodies and uses thereof
JP2022529726A5 (https=)
US20220177578A1 (en) Anti-cd117 antibodies and uses thereof
JP2022529727A5 (https=)
US20210095039A1 (en) Anti-cd252 antibodies, conjugates, and methods of use
EP3740233A2 (en) Compositions and methods for the depletion of cd134+ cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230511

R150 Certificate of patent or registration of utility model

Ref document number: 7280254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150